Telik Announces Preclinical Presentations at AACR Annual Meeting
PALO ALTO, Calif., April 14 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ: TELK) announced today that two abstracts highlighting results from its Research and Development programs will be presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO.
Details of the presentations are as follows:
-- In vivo Characterization and Mechanism of Action of Orally Active
Aurora Kinase/VEGFR Inhibitors; Sunday, April 19, 2009, 1:00 - 5:00pm;
Kinase Inhibitors 1; Abstract # 1764
-- Anti-Tumor Efficacy and Molecular Mechanism of TLK58747; Tuesday,
April 21, 2009, 1:00 -- 5:00pm; Agents Causing DNA Damage or
Proteasome Inhibition; Abstract # 4515
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
Source: Telik, Inc.
CONTACT: Patricia P. Frias, Corporate Communications of Telik, Inc.,
Posted: April 2009